Novel intrapleural therapies for malignant diseases

Respiration

Volumn 83, Issue 4, 2012, Pages 277-292

  Haas, Andrew R ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Extrapleural pneumonectomy; Malignant mesothelioma; Malignant pleural effusion

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; AMIFOSTINE; BETA INTERFERON; BLEOMYCIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; E1A PROTEIN; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GEMCITABINE; INTERLEUKIN 2; LIPOSOME; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PARVOVIRUS VECTOR; PICIBANIL; RECOMBINANT GAMMA INTERFERON; RETROVIRUS VECTOR; SODIUM THIOSULFATE; STAPHYLOCOCCAL SUPERANTIGEN; SUPERANTIGEN; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOSURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG WITHDRAWAL; EOSINOPHILIA; EXTRAPLEURAL PNEUMONECTOMY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; HYPERTHERMIC THERAPY; INJECTION SITE DISCOMFORT; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA EFFUSION; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA CANCER; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; SUICIDE GENE THERAPY; THORAX DRAINAGE; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MALE; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84859138433     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000337060     Document Type: Review

References (81)

1. Sterman DH, Albelda SM: Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma. Respirology 2005;10:266-283. (Pubitemid 41025602)
2. Bone G: Postoperative empyema and survival in lung cancer. Br Med J 1973;2:178.
3. Ruckdeschel JC, Codish SD, Stranahan A, et al: Postoperative empyema improves survival in lung cancer: documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013-1017.
4. Vaisrub S: Empyema in lung cancer: the cloud with a silver lining. JAMA 1973;224:1644.
5. Minasian H, Lewis CT, Evans SJ: Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma. Br Med J 1978;2:1329-1331. (Pubitemid 9062107)
6. Lawaetz O, Halkier E: The relationship between postoperative empyema and long-term survival after pneumonectomy: results of surgical treatment of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1980;14:113-117. (Pubitemid 10149542)
7. Pastorino U, Valente M, Piva L, et al: Empyema following lung cancer resection: risk factors and prognostic value on survival. Ann Thorac Surg 1982;33:320-323. (Pubitemid 12147851)
8. McKneally MF, Maver C, Lininger L, et al: Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 1981;81:485-492. (Pubitemid 11106133)
9. Bakker W, Nijhuis-Heddes JM, Wever Am, et al: Postoperative intrapleural BCG in lung cancer: lack of efficacy and possible enhancement of tumour growth. Thorax 1981;36:870-874. (Pubitemid 12198238)
10. Bakker W, Nijhuis-Heddes JM, van der Velde EA: Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 1986;22:155-159. (Pubitemid 16084103)
11. Refaely Y, Simansky DA, Paley M, et al: Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001;72:366-370. (Pubitemid 32727129)
12. Pinto C, Marino A, Guaraldi M, et al: Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2001;24:143-147. (Pubitemid 32323351)
13. Chang MY, Sugarbaker DJ: Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin 2004;14:549-556. (Pubitemid 39314489)
14. Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ: Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009;138:405-411.
15. Tohda Y, Iwanaga T, Takada M, et al: Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999;45:197-204. (Pubitemid 29213402)
16. Shoji T, Tanaka F, Yanagihara K, et al: Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 2002;121:821-824. (Pubitemid 34251448)
17. Su WC, Lai WW, Chen HH, et al: Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion: a pilot study. Oncology 2003;64:18-24. (Pubitemid 35477950)
18. Matsuzaki Y, Edagawa M, Shimizu T, et al: Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis. Ann Thorac Surg 2004;78:1769-1772, discussion 1772-1773.
19. Jones DR, Taylor MD, Petroni GR, Shu J, Burks SG, Daniel TM, Gillenwater HH: Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol 2010;5:75-81.
20. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H: The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995;12:455-460.
21. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, et al: Transforming growth factorbeta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44. (Pubitemid 24310376)
22. Jarnicki AG, Fitzpatrick DR, Robinson BW, et al: Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 1996;103:1-9. (Pubitemid 26125158)
23. Lew F, Tsang P, Holland JF, et al: High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986;6:225-233. (Pubitemid 16087174)
24. Kagan E: The alveolar macrophage: immune derangement and asbestos-related malignancy. Semin Oncol 1981;8:258-267.
25. Henderson DW, Attwood HD, Constance TJ, et al: Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988;12:367-384.
26. Astoul P, Viallat JR, Laurent JC, et al: Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103:209-213. (Pubitemid 23027260)
27. Christmas TI, Manning LS, Garlepp MJ, et al: Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 1993;13:9-12.
28. Boutin C, Nussbaum E, Monet I, et al: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-2467. (Pubitemid 24320849)
29. Boutin C, Viallat JR, Van Zandwijk N, et al: Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991;67:2033-2037.
30. Douillard JY, Boutin C, Bignon J, Guerin JC, Van Derschueren R, Brandely M: Intrapleural recombinant human gamma interferon (rhγ IFN) in the treatment of malignant pleural mesotheliomas. Proc ASCO 1992;11:307.
31. Yanagawa H, Haku T, Hiramatsu K, et al: Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother 1997;45:93-99. (Pubitemid 27497684)
32. Goey SH, Eggermont AM, Punt CJ, et al: Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995;72:1283-1288.
33. Sartori S, Tassinari D, Ceccotti P, et al: Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 2004;22:1228-1233. (Pubitemid 41079836)
34. Yamaguchi Y, Miyahara E, Oshita A, et al: Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br J Cancer 2003;89:1876-1884. (Pubitemid 37533263)
35. Ikehara M, Oshita F, Suzuki R, et al: Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. J Exp Ther Oncol 2004;4:79-83. (Pubitemid 38552468)
36. Ren S, Terman DS, Bohach G, et al: Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004;126:1529-1539. (Pubitemid 39525027)
37. Wivel NA, Wilson JM: Methods of gene delivery. Hematol Oncol Clin North Am 1998;12:483-501. (Pubitemid 28347550)
38. Curiel DT, Pilewski JM, Albelda SM: Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol 1996;14:1-18. (Pubitemid 126443085)
39. Nagy JA, Shockley TR, Masse EM, et al: Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 1995;2:402-410.
40. Yang L, Hwang R, Pandit L, et al: Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996;224:405-414, discussion 414-417.
41. Batra RK, Olsen JC, Hoganson DK, et al: Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997;272:11736-11743. (Pubitemid 27202738)
42. Monahan PE, Samulski RJ: AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30.
43. Zhang WW: Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999;6:113-138.
44. Yeh P, Perricaudet M: Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997;11:615-623. (Pubitemid 27318279)
45. Wold WS, Doronin K, Toth K, et al: Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999;11:380-386. (Pubitemid 29377903)
46. Smythe WR, Hwang HC, Amin KM, et al: Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-2059. (Pubitemid 24138668)
47. Brody SL, Jaffe HA, Han SK, et al: Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994;5:437-447. (Pubitemid 24304743)
48. Esandi MC, van Someren GD, Vincent AJ, et al: Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997;4:280-287. (Pubitemid 27170719)
49. Batra RK, van Someren GD, Vincent AJ, et al: Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions. Am J Respir Cell Mol Biol 2000;22:613-619. (Pubitemid 30322536)
50. Sterman DH, Treat J, Litzky LA, et al: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092. (Pubitemid 28236516)
51. Chesnoy S, Huang L: Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000;29:27-47. (Pubitemid 30599587)
52. Nagamachi Y, Tani M, Shimizu K, et al: Suicidal gene therapy for pleural metastasis of lung cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Cancer Gene Ther 1999;6:546-553. (Pubitemid 129667829)
53. Hortobagyi GN, Ueno NT, Xia W, et al: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-3433. (Pubitemid 32642196)
54. Tiberghien P: Use of suicide genes in gene therapy. J Leukoc Biol 1994;56:203-209.
55. Mesnil M, Yamasaki H: Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-3999. (Pubitemid 30636571)
56. Elshami AA, Saavedra A, Zhang H, et al: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85-92.
57. Pope IM, Poston GJ, Kinsella AR: The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997;33:1005-1016. (Pubitemid 27310774)
58. Kolls J, Freeman S, Ramesh R, Marroqi A, Weinacker A, Summer W, Schwarzenberger P: The treatment of malignant pleural mesothelioma with gene modified cancer cells: a phase I study. Am J Respir Crit Care Med 1998;157:A563.
59. Schwarzenberger P, Harrison L, Weinacker A, et al: Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998;150:168-174.
60. Harrison LH Jr, Schwarzenberger PO, Byrne PS, et al: Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000;70:407-411.
61. Schwarzenberger P, Byrne P, Gaumer R, Norton J, Harrison L, Marrogi A, Kolls JK: Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 2011;18:906-912.
62. Smythe WR, Hwang HC, Elshami AA, et al: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995;222:78-86.
63. Smythe WR, Kaiser LR, Hwang HC, et al: Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57:1395-1401. (Pubitemid 24216301)
64. Hwang HC, Smythe WR, Elshami AA, et al: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16.
65. Elshami AA, Kucharczuk JC, Zhang HB, et al: Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996;7:141-148. (Pubitemid 26044833)
66. Molnar-Kimber KL, Sterman DH, Chang M, et al: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998;9:2121-2133. (Pubitemid 28463929)
67. Sterman DH, Molnar-Kimber K, Iyengar T, et al: A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511-1518. (Pubitemid 32098762)
68. Leong CC, Marley JV, Loh S, et al: The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol Cell Biol 1997;75:356-359. (Pubitemid 27408041)
69. Addison CL, Braciak T, Ralston R, et al: Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995;92:8522-8526.
70. Mukherjee S, Haenel T, Himbeck R, et al: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000;7:663-670. (Pubitemid 30314050)
71. Rosso R, Rimoldi R, Salvati F, et al: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988;45:253-256.
72. Cascinu S, Isidori PP, Fedeli A, Fedeli SL, Raspugli M, Rossi A, et al: Experience with intrapleural natural beta interferon in the treatment of malignant pleural effusions. Tumori 1991;77:237-238.
73. Odaka M, Sterman DH, Wiewrodt R, et al: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-6212. (Pubitemid 32762558)
74. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al: A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-4466. (Pubitemid 47219714)
75. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, et al: A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18:852-860.
76. Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, et al: A trial of intrapleural adenoviral-mediated interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184:1395-1399.
77. Selvaraj P, Yerra A, Tien L, Shashidharamurthy R: Custom designing therapeutic cancer vaccines: delivery of immunostimulatory molecule adjuvants by protein transfer. Hum Vaccin 2008;4:384-388.
78. Vachani A, Moon E, Wakeam E, Albelda SM: Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010;42:385-393.
79. Giuliano M, Catalano A, Strizzi L, et al: Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000;5:591-596.
80. Dong M, Li X, Hong LJ, Xie R, Zhao HL, Li K, Wang HH, Shin WD, Shen HJ: Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 2008;36:1273-1278.
81. Zhao WZ, Wang JK, Li W, Zhang XL: Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Ai Zheng 2009;28:1324-1327.